Cargando…
Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine
Public health vaccination recommendations for COVID-19 primary series and boosters in previously infected individuals differ worldwide. As infection with SARS-CoV-2 is often asymptomatic, it remains to be determined if vaccine immunogenicity is comparable in all previously infected subjects. This st...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614167/ https://www.ncbi.nlm.nih.gov/pubmed/36311736 http://dx.doi.org/10.3389/fimmu.2022.930252 |
_version_ | 1784820134635896832 |
---|---|
author | Nantel, Sabryna Bourdin, Benoîte Adams, Kelsey Carbonneau, Julie Rabezanahary, Henintsoa Hamelin, Marie-Ève McCormack, Deirdre Savard, Patrice Longtin, Yves Cheng, Matthew P. De Serres, Gaston Corbeil, Jacques Gilca, Vladimir Baz, Mariana Boivin, Guy Quach, Caroline Decaluwe, Hélène |
author_facet | Nantel, Sabryna Bourdin, Benoîte Adams, Kelsey Carbonneau, Julie Rabezanahary, Henintsoa Hamelin, Marie-Ève McCormack, Deirdre Savard, Patrice Longtin, Yves Cheng, Matthew P. De Serres, Gaston Corbeil, Jacques Gilca, Vladimir Baz, Mariana Boivin, Guy Quach, Caroline Decaluwe, Hélène |
author_sort | Nantel, Sabryna |
collection | PubMed |
description | Public health vaccination recommendations for COVID-19 primary series and boosters in previously infected individuals differ worldwide. As infection with SARS-CoV-2 is often asymptomatic, it remains to be determined if vaccine immunogenicity is comparable in all previously infected subjects. This study presents detailed immunological evidence to clarify the requirements for one- or two-dose primary vaccination series for naturally primed individuals. The main objective was to evaluate the immune response to COVID-19 mRNA vaccination to establish the most appropriate vaccination regimen to induce robust immune responses in individuals with prior SARS-CoV-2 infection. The main outcome measure was a functional immunity score (zero to three) before and after vaccination, based on anti-RBD IgG levels, serum capacity to neutralize live virus and IFN-γ secretion capacity in response to SARS-CoV-2 peptide pools. One point was attributed for each of these three functional assays with response above the positivity threshold. The immunity score was compared based on subjects’ symptoms at diagnosis and/or serostatus prior to vaccination. None of the naïve participants (n=14) showed a maximal immunity score of three following one dose of vaccine compared to 84% of the previously infected participants (n=55). All recovered individuals who did not have an immunity score of three were seronegative prior to vaccination, and 67% had not reported symptoms resulting from their initial infection. Following one dose of vaccine, their immune responses were comparable to naïve individuals, with significantly weaker responses than individuals who were symptomatic during infection. These results indicate that the absence of symptoms during initial infection and negative serostatus prior to vaccination predict the strength of immune responses to COVID-19 mRNA vaccine. Altogether, these findings highlight the importance of administering the complete two-dose primary regimen and following boosters of mRNA vaccines to individuals who experienced asymptomatic SARS-CoV-2 infection. |
format | Online Article Text |
id | pubmed-9614167 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96141672022-10-29 Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine Nantel, Sabryna Bourdin, Benoîte Adams, Kelsey Carbonneau, Julie Rabezanahary, Henintsoa Hamelin, Marie-Ève McCormack, Deirdre Savard, Patrice Longtin, Yves Cheng, Matthew P. De Serres, Gaston Corbeil, Jacques Gilca, Vladimir Baz, Mariana Boivin, Guy Quach, Caroline Decaluwe, Hélène Front Immunol Immunology Public health vaccination recommendations for COVID-19 primary series and boosters in previously infected individuals differ worldwide. As infection with SARS-CoV-2 is often asymptomatic, it remains to be determined if vaccine immunogenicity is comparable in all previously infected subjects. This study presents detailed immunological evidence to clarify the requirements for one- or two-dose primary vaccination series for naturally primed individuals. The main objective was to evaluate the immune response to COVID-19 mRNA vaccination to establish the most appropriate vaccination regimen to induce robust immune responses in individuals with prior SARS-CoV-2 infection. The main outcome measure was a functional immunity score (zero to three) before and after vaccination, based on anti-RBD IgG levels, serum capacity to neutralize live virus and IFN-γ secretion capacity in response to SARS-CoV-2 peptide pools. One point was attributed for each of these three functional assays with response above the positivity threshold. The immunity score was compared based on subjects’ symptoms at diagnosis and/or serostatus prior to vaccination. None of the naïve participants (n=14) showed a maximal immunity score of three following one dose of vaccine compared to 84% of the previously infected participants (n=55). All recovered individuals who did not have an immunity score of three were seronegative prior to vaccination, and 67% had not reported symptoms resulting from their initial infection. Following one dose of vaccine, their immune responses were comparable to naïve individuals, with significantly weaker responses than individuals who were symptomatic during infection. These results indicate that the absence of symptoms during initial infection and negative serostatus prior to vaccination predict the strength of immune responses to COVID-19 mRNA vaccine. Altogether, these findings highlight the importance of administering the complete two-dose primary regimen and following boosters of mRNA vaccines to individuals who experienced asymptomatic SARS-CoV-2 infection. Frontiers Media S.A. 2022-10-14 /pmc/articles/PMC9614167/ /pubmed/36311736 http://dx.doi.org/10.3389/fimmu.2022.930252 Text en Copyright © 2022 Nantel, Bourdin, Adams, Carbonneau, Rabezanahary, Hamelin, McCormack, Savard, Longtin, Cheng, De Serres, Corbeil, Gilca, Baz, Boivin, Quach and Decaluwe https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Nantel, Sabryna Bourdin, Benoîte Adams, Kelsey Carbonneau, Julie Rabezanahary, Henintsoa Hamelin, Marie-Ève McCormack, Deirdre Savard, Patrice Longtin, Yves Cheng, Matthew P. De Serres, Gaston Corbeil, Jacques Gilca, Vladimir Baz, Mariana Boivin, Guy Quach, Caroline Decaluwe, Hélène Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine |
title | Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine |
title_full | Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine |
title_fullStr | Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine |
title_full_unstemmed | Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine |
title_short | Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine |
title_sort | symptomatology during previous sars-cov-2 infection and serostatus before vaccination influence the immunogenicity of bnt162b2 covid-19 mrna vaccine |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614167/ https://www.ncbi.nlm.nih.gov/pubmed/36311736 http://dx.doi.org/10.3389/fimmu.2022.930252 |
work_keys_str_mv | AT nantelsabryna symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine AT bourdinbenoite symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine AT adamskelsey symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine AT carbonneaujulie symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine AT rabezanaharyhenintsoa symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine AT hamelinmarieeve symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine AT mccormackdeirdre symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine AT savardpatrice symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine AT longtinyves symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine AT chengmatthewp symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine AT deserresgaston symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine AT corbeiljacques symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine AT gilcavladimir symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine AT bazmariana symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine AT boivinguy symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine AT quachcaroline symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine AT decaluwehelene symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine |